About this item:

34 Views | 21 Downloads

Author Notes:

Alexis N. Simpkins


The Neurotherapeutics Symposium 2019: Edilberto Amorim, Carolina Barnett-Tapia, Jeremy Brown, Katharina M. Busl, Mackenzie Cervenka, Jan Claassen, Monica Dhakar, Layne Dylla, Marie-Carmelle Elie, Mark Etherton, Kevin Fiscella, Brandon Foreman, Peter Forgacs, Robert C. Griggs, Marc Halterman, Andrea Harriott, Lawrence J. Hirsch, Sara Hocker, Robert Holloway, Rebecca Jules, Adam G. Kelly, Daniel Lackland, Mackenzie P. Lerario, Karlo J. Lizarraga, Carolina B. Maciel, Lisa H. Merck, Gordon Mitchell, Laura B. Ngwenya, Raul G. Nogueira, Clifford Pierre, Javier Provencio, Alejandro A. Rabenstein, Debra Roberts, Clio Rubinos, Eugene Scharf, Kevin N. Sheth, Alexis N. Simpkins, Cleopatra Thurman, Lauren Ullrich, and Christopher Zammit.

We appreciate the contribution and presentations from the speakers and moderators at the conference, including: Edilberto Amorim, MD (University of California San Francisco, Harvard Medical School, Massachusetts Institute of Technology); Carolina Barnett-Tapia, MD, PhD (University Health Network—Toronto General Hospital); Jeremy Brown, MD (Office of Emergency Care Research NIH); Katharina M. Busl, MD, MS (University of Florida); Mackenzie Cervenka, MD (Johns Hopkins University); Jan Claassen, MD, PhD (Columbia University Medical Center); Monica Dhakar, MD, MS (Emory University); Layne Dylla, MD (University of Rochester); Marie-Carmelle Elie, MD, RDMS (University of Florida); Mark Etherton, MD, PhD (Harvard Medical School); Kevin Fiscella, MD, MPH (University of Rochester); Brandon Foreman, MD (University of Cincinnati); Peter Forgacs, MD (Weill Cornell Medical College); Robert C Griggs (University of Rochester); Marc Halterman, MD, PhD (University of Rochester); Andrea Harriott, MD, PhD (Harvard Medical School); Lawrence J Hirsch (Yale University); Sara Hocker, MD (Mayo Clinic); Robert Holloway (University of Rochester); Rebecca Jules (University of Florida); Adam G. Kelly (University of Rochester); Daniel Lackland, Dr. PH (Medical University of South Carolina); Mackenzie P Lerario, MD (Weill Cornell Medical College); Karlo J. Lizarraga, MD, MS (University of Rochester); Carolina B. Maciel, MD, MSCR (University of Florida, University of Utah, Yale University); Lisa H. Merck, MD, MPH (University of Florida); Gordon Mitchell, PhD (University of Florida); Laura B. Ngwenya, MD, PhD (University of Cincinnati); Raul G. Nogueira, MD (Emory University); Clifford Pierre, MD (University of Rochester); Javier Provencio, MD, PhD (University of Virginia); Alejandro A. Rabenstein, MD (Mayo Clinic); Debra Roberts, MD, PhD (University of Rochester); Clio Rubinos, MD (University of North Carolina); Eugene Scharf, MD (Mayo Clinic); Kevin N. Sheth, MD (Yale University); Alexis N. Simpkins, MD, PhD, MSCR (University of Florida); Cleopatra Thurman, MD (University of Michigan); Lauren Ullrich, MS, PhD (NINDS); Christopher Zammit, MD (University of Rochester). We also want to thank Franklin D. Echevarria, PhD (University of Florida) for assistance with manuscript submission and formatting.

Dr. Simpkins has nothing to disclose; Dr. Busl reports personal fees from Guidepoint Global, personal fees from Techspert, other from American Academy of Neurology, outside the submitted work; Dr. Amorim has nothing to disclose; Dr. Barnett reports grants from Octapharma, grants from Grifols, personal fees from Alexion, personal fees from Takeda, personal fees from Akcea, personal fees from CSL, outside the submitted work; Dr. Cervenka reports grants and personal fees from Nutricia, grants from Vitaflo, grants from BrightFocus Foundation, personal fees from Demos, personal fees from Glut2 Deficiency Foundation, outside the submitted work; Dr. Dhakar reports personal fees from Adamas Pharmaceuticals, outside the submitted work; Dr. Etherton has nothing to disclose; Ms. Fung has nothing to disclose; Dr. Griggs reports grants from Strongbridge Biopharma, grants from Attune Medical, during the conduct of the study; grants from PTC Therapeutics (formerly Marathon Pharma), grants from Sarepta Therapeutics, grants from Foundation to Eradicate Duchenne (FED), grants from Muscular Dystrophy Association (MDA), grants from Parent Project Muscular Dystrophy (PPMD), outside the submitted work; Dr. Holloway has nothing to disclose; Dr. Kelly has nothing to disclose; Dr. Khan has nothing to disclose; Dr. Lizarraga has nothing to disclose; Ms. Madagan has nothing to disclose; Dr. Merck reports grants from NIH, grants from DoD, grants from Bill and Melinda Gates Foundation, outside the submitted work; Dr. Mestre has nothing to disclose; Dr. Rabinstein has nothing to disclose; Dr. Rubinos has nothing to disclose; Dr. Youn has nothing to disclose; Dr. Maciel has nothing to disclose.

See publication for full list of authors.


Research Funding:

NINDS (R13 NS11956-01), the McKnight Brain Institute and industry (Sophysa, UCB, Moberg, Persyst, NeurOptics, GW Pharmaceuticals, Minnetronix Neuro, Strongbridge, Raumedics, Attun).


  • Conference proceedings
  • Diversity excellence
  • Neurocritical care
  • Team science
  • Translational research
  • Emergencies
  • Female
  • Humans
  • Nervous System Diseases

Proceedings from the Neurotherapeutics Symposium on Neurological Emergencies: Shaping the Future of Neurocritical Care

Show all authors Show less authors


Journal Title:

Neurocritical Care


Volume 33, Number 3


, Pages 636-645

Type of Work:

Article | Final Publisher PDF


Effective treatment options for patients with life-threatening neurological disorders are limited. To address this unmet need, high-impact translational research is essential for the advancement and development of novel therapeutic approaches in neurocritical care. “The Neurotherapeutics Symposium 2019—Neurological Emergencies” conference, held in Rochester, New York, in June 2019, was designed to accelerate translation of neurocritical care research via transdisciplinary team science and diversity enhancement. Diversity excellence in the neuroscience workforce brings innovative and creative perspectives, and team science broadens the scientific approach by incorporating views from multiple stakeholders. Both are essential components needed to address complex scientific questions. Under represented minorities and women were involved in the organization of the conference and accounted for 30–40% of speakers, moderators, and attendees. Participants represented a diverse group of stakeholders committed to translational research. Topics discussed at the conference included acute ischemic and hemorrhagic strokes, neurogenic respiratory dysregulation, seizures and status epilepticus, brain telemetry, neuroprognostication, disorders of consciousness, and multimodal monitoring. In these proceedings, we summarize the topics covered at the conference and suggest the groundwork for future high-yield research in neurologic emergencies.

Copyright information:

© The Author(s) 2020.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Export to EndNote